Xuefen Li

Dr. Xuefen Li

the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BYBo Ye
Bo Ye
YSYifei Shen
Yifei Shen
HCHui Chen
Hui Chen
SLSha Lin
Sha Lin
WMweilin mao
weilin mao
XLXuefen Li
Xuefen Li
Hepatitis B virus (HBV) infection is still a major public health problem worldwide. We aimed to identify new, non-invasive biomarkers for the early diagnosis of chronic HBV-related diseases, reveal alterations in the progression of chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC). Here, exosomes were isolated and characterized through size exclusion chromatography and nanoparticle tracking analysis. Profiles of differentially expressed proteins (DEPs) were analyzed through liquid chromatography-tandem mass spectrometry (LC–MS/MS), Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes analyses. Results showed that the DEPs, including CO9, LBP, SVEP1, and VWF levels in extracellular vesicles (EVs) were significantly higher in CHB than in healthy controls (HCs). VWF expression levels in EVs were significantly lower in CHB than in those with LC. KV311 expression levels in EVs were significantly higher, whereas LBP levels were significantly lower in patients with CHB than in those with HCC. All biomarkers seemed to exhibit a high diagnostic capacity for HBV-related liver disease. Patients with HBV-induced chronic liver disease exhibit characteristic protein profiles in their EVs. Thus, serum exosomes may be used as novel, liquid biopsy biomarkers to provide useful clinical information for the diagnosis of HBV-related liver diseases at different stages.

11 March 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
XLXuefen Li
Xuefen Li
XLXia Liu
Xia Liu
WWweilin wang
weilin wang
Chronic hepatitis B virus (HBV) infection is a risk factor for liver cirrhosis (LC) and hepatocellular carcinoma (HCC), however, little is known about the mechanisms involved in the progression of HBV-related diseases. It has been well acknowledged that host immune response was closely related to the clinical outcomes of patients with HBV infection. As the factors closely related to the immunomodulatory process, cytokines are crucial in the cell-cell communication and the host responses to HBV infection. Recently, a newly discovered cytokine, designated as interleukin-35 (IL-35), has been proved to be essential for the progression of chronic HBV infection, the development of cirrhosis, the transformation of cirrhosis to HCC, and the metastasis of HCC. Specifically, it showed various biological activities such as inhibiting the HBV-specific cytotoxic T lymphocyte (CTL) proliferation and cytotoxicity, deactivating the immature effector T-cells (Teffs), as well as delaying the proliferation of dendritic cells. It regulated the immune responses by acting as a “brake” on the activation of Teffs, which subsequently played important roles in the pathogenesis of various inflammatory diseases and malignancies. In this review, we focused on the most recent data on the relationship between IL-35 and chronic HBV infection, LC and HCC.

21 April 2025 in Journal of Medical Virology
Verified
Journal Article
Closed access
LHLi Huang
Li Huang
BYBo Ye
Bo Ye
FCFeinan Cao
Feinan Cao
BRBing Ruan
Bing Ruan
XLXuefen Li
Xuefen Li

24 April 2018 in Oncology Letters
Verified
Journal Article
Open access
PDF file
Feng ChenFeng Chen
Feng Chen
QZQian Zhang
Qian Zhang
YWYanjin Wang
Yanjin Wang
SWSiwen Wang
Siwen Wang
SFShawein Feng
Shawein Feng
CDChong Ding
Chong Ding
Oral mucosal melanoma (OMM) is an aggressive malignant tumor derived from melanocytes in the oral cavity. The genetic etiology of OMM has not been extensively investigated to date. In the present study, the aim was to detect novel gene mutations in patients with OMM. Mutation analysis of KIT, BRAF and NRAS was conducted by polymerase chain reaction. In addition, the relevant literature was searched using the PubMed database, and previous findings were compared with the results of the present study. Among the 9 patients with OMM examined, KIT, BRAF and NRAS mutations were detected, and these mutations were all observed at a frequency of 11.1% (1/9 patients). Notably, a novel FMNL2 mutation in 2 patients with OMM was identified by exome sequencing. In conclusion, the current study observed KIT, BRAF, NRAS and FMNL2 mutations in patients with OMM, which may be of benefit for elucidating the underlying mechanism of OMM pathogenesis.

20 August 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YLYongtao Li
Yongtao Li
CWChengfei Wang
Chengfei Wang
XYXuying Yin
Xuying Yin
LJLili Jiang
Lili Jiang
XLXuefen Li
Xuefen Li
JYJiezuan Yang
Jiezuan Yang

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
XLXuefen Li
Xuefen Li
HKHaishen Kong
Haishen Kong
LTLi Tian
Li Tian
QZQiaoyun Zhu
Qiaoyun Zhu
YWYiyin Wang
Yiyin Wang
YCYu Chen
Yu Chen
Costimulatory signals are critical for antiviral immunity. The aim of this study was to evaluate the change of costimulatory molecule CD28 on circulating CD8+T cells in chronic hepatitis B patients (CHB). Seventy CHB patients and fifty-six healthy controls were included, and forty-eight CHB patients were recruited for 52 weeks of longitudinal investigation. The proportions of circulating CD8+CD28+and CD8+CD28−subpopulations were determined by flow cytometry, and the CD8+CD28+/CD8+CD28−T cells ratio was calculated. Compared with the subpopulation in healthy controls, high proportions of CD8+CD28−subpopulation were observed in CHB patients. Similarly, the CD8+CD28+/CD8+CD28−T cells ratio was significantly decreased in CHB patients compared with healthy controls and correlated significantly with hepatitis B virus (HBV) loads. High proportions of CD8+CD28−subpopulation and low CD8+CD28+/CD8+CD28−T cells ratio were observed in hepatitis B e antigen- (HBeAg-) positive individuals as compared with that in HBeAg-negative subjects. A significant decrease in CD8+CD28−subpopulation, increase in CD8+CD28+subpopulation, and CD8+CD28+/CD8+CD28−T cells ratio were seen in those patients who received efficient antiviral therapy. Thus, aberrant CD28 expression on circulating CD8+T cells and the CD8+CD28+/CD8+CD28−T cells ratio reflect the dysregulation of T cell activation and are related to the pathogenesis of chronic HBV infection.